Cue Health Receives FDA Emergency Use Authorization for Its Rapid, Portable, Molecular Point-of-Care COVID-19 Test
12 juin 2020 08h00 HE
|
Cue Health Inc.
SAN DIEGO, June 12, 2020 (GLOBE NEWSWIRE) -- Cue Health Inc. (“Cue”), a healthcare technology company, announced today that it has received Emergency Use Authorization (“EUA”) from the U.S. Food and...
Innovation Pharmaceuticals Collaborating with Regional Biocontainment Lab on Grant Application to Research Brilacidin as a Pan-Coronavirus Therapeutic
11 juin 2020 07h30 HE
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today the Company and researchers...
Cue Health Closes $100 Million Series C Financing to Support Launch of Rapid Molecular Testing Platform
10 juin 2020 09h00 HE
|
Cue Health Inc.
SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Cue Health Inc. (“Cue”), a healthcare technology company, announced today the close of its Series C financing round, raising $100 million in new capital....
Dennis P. Calvert, President & CEO of BioLargo, Inc. Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com
08 juin 2020 08h00 HE
|
BioLargo, Inc.
AUSTIN, Texas, June 08, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and BioLargo, Inc. (OTCQB:BLGO)(“the Company”), developer of sustainable technologies and a full-service environmental...
Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study
28 mai 2020 03h00 HE
|
Atriva Therapeutics GmbH
ATR-002 mode of action inhibits SARS-CoV-2 viral propagation and prevents the cytokine storm as demonstrated in preclinical studiesAtriva’s lead product candidate is the only host-targeted antiviral...
Innovation Pharmaceuticals Receives Data from Public Health Research Institute Showing Brilacidin Inhibits SARS-CoV-2 (COVID-19) in a Human Cell Line
26 mai 2020 08h00 HE
|
Innovation Pharmaceuticals Inc.
Brilacidin showed a dose-dependent inhibitory response in a human kidney cell line expressing hACE2Data supports Brilacidin’s potential to prevent SARS-CoV-2 binding to the hACE2 receptor, the method...
Innovation Pharmaceuticals’ Brilacidin Reduces Viral Titer of SARS-CoV-2 (COVID-19) by 75 percent After Only 1 Hour of Preincubation in In Vitro Study at BSL-3 Facility; Demonstrates Potent and Rapid Virucidal Activity
19 mai 2020 07h30 HE
|
Innovation Pharmaceuticals Inc.
Experiment supports Brilacidin’s therapeutic potential as a COVID-19 treatment and as a prophylactic agent against COVID-19 WAKEFIELD, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Innovation...
BioNTech veröffentlicht Ergebnisse des ersten Quartals 2020 und Informationen zur Geschäftsentwicklung
12 mai 2020 08h05 HE
|
BioNTech SE
Globale Phase-1/2-Studie für BNT162-Impfstoffprogramm zur Prävention einer COVID-19-Infektion befindet sich in der Dosiseskalationsphase in Europa und den Vereinigten Staaten; in beiden Regionen wurde...
BioNTech Announces First Quarter 2020 Financial Results and Corporate Progress
12 mai 2020 08h05 HE
|
BioNTech SE
Global Phase 1/2 clinical trial for BNT162 vaccine program to prevent COVID-19 infection in dose escalation phase in Europe and the U.S.; first cohorts dosed in both regionsBNT122 Phase 1/2 trial...
Translate Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
07 mai 2020 16h26 HE
|
Translate Bio, Inc.
-- Pursuing development of mRNA vaccine against COVID-19 through expanded collaboration with Sanofi Pasteur -- -- Existing large-scale manufacturing capacity expected to help meet needs of...